Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.
Company profile
Ticker
PTLA
Exchange
Website
CEO
J. Scott Garland
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
PTLA stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
13 Jul 20
POSASR
Automatic shelf registration (post-effective amendment)
2 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Jul 20
25-NSE
Exchange delisting
2 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Jul 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Jul 20
Institutional ownership, Q1 2023
4.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 3.55 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Flynn James E | 3.55 mm | $0.00 |